

> Indications for coronary angiography in stable CAD,  無症狀 病人, and others

# CORONARY ANGIOGRAPHY AND REVASCULARIZATION

### Indications for coronary angiography in stable CAD,  無症狀 病人, and others

• CCS class III–IV angina despite med Rx, angina + systolic dysfxn, or unexplained low EF

• High-risk stress test findings (qv) or uncertain dx after noninv testing (& info will ∆ mgmt)

• Occupational need for definitive dx (eg, pilot) or inability to undergo noninvasive testing

• Survivor of SCD, polymorphic VT, sustained monomorphic VT

• Suspected spasm; nonathero cause of ischemia (eg, anomalous coronary; CCTA preferred)

• Preop workup in select 病人 undergoing organ transplant eval (CCTA reasonable)

### Precath checklist & periprocedural pharmacotherapy

• Peripheral arterial exam (radial, femoral, DP, PT pulses; bruits); ✔ palmar arch intact (eg, with pulse oximetry & plethysmography). ✔ can lie flat, NPO >6 h.

• ✔CBC, PT, Cr; hold ACEI/ARB if renal dysfxn (see “CIAKI”). Blood bank sample.

• ASA 325 mg × 1. Timing of P2Y12 inhib debated. as soon as possible for STEMI. ? preRx NSTEACS if clopi (_JAMA_ 2012;308:2507) or ticagrelor, not prasugrel. Cangrelor (IV P2Y12 inhib) ↓ peri-

PCI events vs. clopi without PreRx (_NEJM_ 2013;368:1303). ? statin preRx (_Circ_ 2011;123:1622).

### Coronary revascularization in stable CAD (_NEJM_ 2016;374:1167; _JACC_ 2017;69:2212)

• Optimal med Rx (**OMT**): preferred 1st line if stable disease without critical anatomy & with 正常 EF

• **PCI:** ↓ angina; no ∆ exercise time (_Lancet_ 2018;391:31) or D/MI (_NEJM_ 2015;373:1204);

if ≥1 stenosis with FFR (qv) ≤0.8, ↓ urg revasc & MI c/w OMT (_NEJM_ 2018;379:250)

• **CABG** (_NEJM_ 2016;374:1954): in older studies, ↓ mort. c/w OMT if 3VD, LM, 2VD with crit. prox LAD, esp. if ↓ EF; recently confirmed if multivessel dis. & EF <35% (_NEJM_ 2016;374:1511); radial artery ↑ patency & ↓ MACE vs. saphenous vein grafts (_NEJM_ 2018;378:2069); less complete revasc & possibly ↑ mort. with off vs. on-pump (_NEJM_ 2016;375:2359 & 377:623)

• If revasc deemed necessary, _PCI_ if limited # of discrete lesions, 正常 EF, no DM, poor operative candidate; _CABG_ if extensive or diffuse disease, ↓ EF, DM or valvular disease; SYNTAX score II: ID 病人 with ↑ benefit with CABG (_Lancet_ 2013;381:639); if multivessel disease with high complexity or DM, CABG ↓ mortality (_Lancet_ 2018;391:939); if LM disease, PCI ≈ CABG, but ↑ repeat revasc with PCI (_JAMA Cardiol._ 2017;2:1079)

### PCI and peri-PCI interventions

• **Access:** radial ↓ bleed/vasc comp (? ↓ death in ACS) vs. fem (_Circ CV Interv_ 2018;11:e000035)

• **Fractional flow reserve** (FFR): ratio of max flow (induced by adenosine) distal vs. prox to stenosis to ID hemodyn. signif. lesions (≤0.80). Instantaneous wave-free ratio (iFR) similar to FFR, doesn’t require vasodilator; iFR threshold ≤0.89 (_NEJM_ 2017;376:1813 & 1824).

• Balloon angioplasty by itself rare b/c elastic recoil; reserved for lesions too narrow to stent

• **Bare metal stents (BMS):** ↓ restenosis & repeat revasc c/w angioplasty alone

• **Drug-eluting stents (DES):** latest DES ↓ cardiac death or MI, repeat revasc, and stent thrombosis vs. BMS (_Lancet_ 2019;393:2503)

• Antiplt Rx: DAPT (ASA 81 + P2Y12 inhib) in SIHD for 4 wk (BMS) or ≥6 mo (DES); in _ACS_ (qv) for 12 mo and possibly beyond (_JAMA Cards_ 2016;1:627). Data emerging for DAPT for just 1 mo, followed by P2Y12 inhib for 11 mo (_Lancet_ 2018;392:940; _JAMA_ 2019;321:2414 & 2428).

• If need long-term oral anticoag, consider clopi+DOAC and consider stopping ASA (? after ~1 wk) as ↓ bleed, but trend small ↑ ischemic risk (_Lancet_ 2013;381:1107 & _NEJM_ 2019;380:1509)

### Post-PCI complications (_NEJM_ 2017;377:1513)

• Postprocedure ✔ vascular access site, distal pulses, ECG, CBC, Cr

• **Bleeding:** if hematoma/overt bleeding → **manual compression**, reverse/stop anticoag.

_Retroperitoneal bleed:_ may 表現為 ↓ Hct ± back pain; ↑ HR & ↓ BP late; Dx with abd/pelvic CT (I–); Rx: reverse/stop anticoag (d/w interventionalist), IVF/PRBC/plts as required.

• **Vascular damage** (~1% of dx angio, ~5% of transfemoral PCI; _Circ_ 2007;115:2666)

Pseudoaneurysm: triad of pain, expansile mass, systolic bruit; Dx: U/S; Rx (if pain or >2 cm): manual or U/S-directed compression, thrombin injection, or surgical repair

AV fistula: continuous bruit; Dx: U/S; Rx: surgical repair if large or 症狀

LE ischemia (emboli, dissection, clot): cool, mottled extremity, ↓ distal pulses; Dx: pulse volume recording (PVR), angio; Rx: percutaneous or surgical repair

• **Peri-PCI MI:** >5× ULN of Tn/CK-MB + either 症狀 or ECG/angio ∆s; Qw MI in <1%

• **Contrast-induced AKI:** within 48 h, peak 3–5 d; pre-hydration reasonable (see “CIAKI”)

• **Cholesterol emboli syndrome** (typically in middle-aged & elderly and with Ao atheroma)

renal failure (late and progressive, ± eos in urine); mesenteric ischemia (abd pain, LGIB, pancreatitis); intact distal pulses but livedo pattern and toe necrosis

• **Stent thrombosis:** mins-yrs after PCI, typically 表現為 AMI. Due to mech prob. (stent underexpansion or unrecognized dissection, typically presents early) or d/c of antiplt Rx; espec if d/c both ASA & P2Y12 inhib (_JAMA_ 2005;293:2126).

• **In-stent restenosis:** mos after PCI, typically 表現為 gradual ↑ angina (10% 表現為 ACS).

Due to combination of elastic recoil and neointimal hyperplasia; ↓ with DES vs. BMS.
